Filing Flows › Jazz Pharmaceuticals (JAZZ) › Q2 2026 › vs Q1 2026
Jazz Pharmaceuticals (JAZZ) Q2 2026 vs Q1 2026 (quarter over quarter)
Jazz Pharmaceuticals's revenue rose $139M (+13%) from $1.1B in Q1 2026 to $1.2B in Q2 2026. Operating margin 20.5% against 31.5% (-10.9 pts).
Jazz Pharmaceuticals, Q2 2026: revenue $1.2B (+16% year over year), operating margin 20.5%, net earnings $193M, operating cash flow $416M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 20.5% | 31.5% | -10.9 pts |
| Net margin | 16.0% | 27.4% | -11.5 pts |
| Free cash flow margin | 32.9% | 36.3% | -3.4 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.2B | $1.1B | $139M | +13% |
| Operating profit | $248M | $337M | −$88.4M | -26% |
| Costs & expenses | $960M | $732M | $228M | +31% |
| Pre-tax earnings | $211M | $299M | −$88.2M | -29% |
| Other expense, net | $37.2M | $37.4M | −$200K | -0.5% |
| Research & development | $208M | $196M | $11.5M | +6% |
| SG&A | $389M | $353M | $36.5M | +10% |
| Other operating costs | $363M | $184M | $180M | +98% |
| Net earnings | $193M | $293M | −$100M | -34% |
| Income tax | $18.1M | $6.1M | $12.0M | +197% |
| Depreciation & amortization | $179M | $181M | −$2.3M | -1% |
| Share-based compensation | $73.3M | $74.5M | −$1.2M | -2% |
| Working capital & other | $29.5M | $141M | −$111M | -79% |
| Operating cash flow | $416M | $408M | $7.5M | +2% |
| Free cash flow (OCF − capex) | $398M | $388M | $9.1M | +2% |
| Capital expenditures | $18.1M | $19.7M | −$1.6M | -8% |
Questions
How much did Jazz Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Jazz Pharmaceuticals's revenue rose $139M (+13%) from $1.1B in Q1 2026 to $1.2B in Q2 2026. Operating margin 20.5% against 31.5% (-10.9 pts).